AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
- Details
- Category: AstraZeneca

AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77% (95% confidence interval (CI): 46, 90), compared to placebo.
Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrates improved immune response and protection in preclinical study
- Details
- Category: GlaxoSmithKline

Pfizer and BioNTech announce submission of initial data to U.S. FDA to support booster dose of COVID-19 vaccine
- Details
- Category: Pfizer

VTX-801 receives U.S. FDA Fast Track designation for the treatment of Wilson Disease
- Details
- Category: Pfizer

Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
- Details
- Category: Bayer

Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development
- Details
- Category: Sanofi

Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation
- Details
- Category: Eli Lilly and Company

More Pharma News ...
- GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab
- Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people
- Pfizer and BioNTech to provide U.S. government with an additional 200 million doses of COVID-19 vaccine
- AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity
- Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19
- Pfizer and BioNTech announce collaboration with Biovac to manufacture and distribute COVID-19 vaccine doses within Africa
- U.S. FDA grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 vaccine